By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.
FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.
Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.